Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec;6(2):233-241.
doi: 10.1007/s40123-017-0098-2. Epub 2017 Jul 20.

An Update on Implants for Minimally Invasive Glaucoma Surgery (MIGS)

Ejaz Ansari  1   2
Affiliations
Review

An Update on Implants for Minimally Invasive Glaucoma Surgery (MIGS)

Ejaz Ansari. Ophthalmol Ther. 2017 Dec.

Erratum in

Abstract

For several years, the gold standard for surgical treatment of glaucoma has been trabeculectomy. Although very successful at reducing intraocular pressure (IOP), there are several potential complications of trabeculectomy, including sight-threatening ones. This has stimulated much research aimed at the development of new and effective procedures to lower IOP with an enhanced safety profile. Minimally invasive glaucoma surgery (MIGS) procedures prioritise patient safety but also demonstrate efficacy in reducing IOP. We performed an online search of peer-reviewed literature using PubMed, entering keywords relevant to this clinical discipline. In summary, there is a lack of long-term safety and efficacy data, a lack of comparative data and a lack of data on standalone (i.e. without simultaneous cataract surgery) procedures. Most implants are not yet FDA approved. Although not exhaustive, since it does not discuss MIGS procedures that are not implants, this article summarises the range of different MIGS implants that are available to the ophthalmic surgeon.

Keywords: CyPass; Glaucoma; Hydrus; Implant; MIGS; Microshunt; Phaco; Stent; XEN; iStent.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
iStent® (Glaukos Corporation, Laguna Hills, CA, USA) (a) and iStent Inject® (Glaukos Corporation) (b). Figure used courtesy of Glaukos Corporation
Fig. 2
Fig. 2
CyPass implant. Sourced from the FDA website on 1/6/2017
Fig. 3
Fig. 3
XEN implant. Image courtesy of Allergan
Fig. 4
Fig. 4
InnFocus microshunt. Image courtesy of InnFocus
See this image and copyright information in PMC

References

    1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081–2090. doi: 10.1016/j.ophtha.2014.05.013. - DOI - PubMed
    1. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, Early Manifest Glaucoma Trial Group Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–1279. doi: 10.1001/archopht.120.10.1268. - DOI - PubMed
    1. Lemij HG, Hoevenaars JG, van der Windt C, Baudouin C. Patient satisfaction with glaucoma therapy: reality or myth? Clin Ophthalmol. 2015;9:785–93. - PMC - PubMed
    1. Leahy KE, White AJ. Selective laser trabeculoplasty: current perspectives. Clin Ophthalmol. 2015;9:833–841. - PMC - PubMed
    1. Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC, Tube Versus Trabeculectomy Study Group Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up. Am J Ophthalmol. 2012;153:804–814. doi: 10.1016/j.ajo.2011.10.024. - DOI - PMC - PubMed

LinkOut - more resources